<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">endofocus</journal-id><journal-title-group><journal-title xml:lang="ru">FOCUS Эндокринология</journal-title><trans-title-group xml:lang="en"><trans-title>FOCUS. Endocrinology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-0177</issn><issn pub-type="epub">2713-0185</issn><publisher><publisher-name>ООО "Издательство "Перо"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.62751/2713-0177-2025-6-2-11</article-id><article-id custom-type="elpub" pub-id-type="custom">endofocus-50</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL CASE</subject></subj-group></article-categories><title-group><article-title>Клинический случай использования системы закрытой петли в контроле сахарного диабета 1 типа</article-title><trans-title-group xml:lang="en"><trans-title>A clinical case of the use of a closed loop system in the treatment of type 1 diabetes mellitus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6826-5924</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Теплова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Teplova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Теплова Анна Сергеевна – ассистент кафедры эндокринологии ИКМ</p><p>г. Москва</p></bio><bio xml:lang="en"><p>Anna S. Teplova – Assistant at the Department of Endocrinology, Institute of Clinical Medicine</p><p>Moscow</p></bio><email xlink:type="simple">anna_kochina_@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пархоменко</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Parkhomenko</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пархоменко Александр Дмитриевич – к.м.н., врач-эндокринолог</p><p>г. Москва</p></bio><bio xml:lang="en"><p>Alexander D. Parkhomenko –C. Sci. (Med.), endocrinologist</p><p>Moscow</p></bio><email xlink:type="simple">parchomenko@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1103-114X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петросян</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrosyan</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Петросян Карина Аркадьевна – врач-эндокринолог</p><p>г. Москва</p></bio><bio xml:lang="en"><p>Karina A. Petrosyan – endocrinologist</p><p>Moscow</p></bio><email xlink:type="simple">dr_kapetrosyan@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБОУ «Городская клиническая больница им. В.П. Демихова Департамента здравоохранения г. Москвы»</institution></aff><aff xml:lang="en"><institution>State Clinical Hospital named after V.P. Demikhov</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>25</day><month>06</month><year>2025</year></pub-date><volume>6</volume><issue>2</issue><issue-title>Кардиоэндокринология</issue-title><elocation-id>82–88</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Теплова А.С., Пархоменко А.Д., Петросян К.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Теплова А.С., Пархоменко А.Д., Петросян К.А.</copyright-holder><copyright-holder xml:lang="en">Teplova A.S., Parkhomenko A.D., Petrosyan K.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://endofocus.elpub.ru/jour/article/view/50">https://endofocus.elpub.ru/jour/article/view/50</self-uri><abstract><p>Актуальность проблемы сахарного диабета 1 типа (СД1) со временем не сдает позиций в силу особенностей течения заболевания, необходимости радикальной коррекции образа жизни, что приводит к снижению качества жизни пациентов, а также высокой вероятности ранней инвалидизации и смертности в молодом возрасте. Неудовлетворительный гликемический контроль при СД1 тесно взаимосвязан как с риском быстрого развития хронических осложнений, так и с вероятностью острых осложнений. Достижение оптимального гликемического контроля на инсулинотерапии требует частого контроля гликемии, детального понимания правил подсчета хлебных единиц (ХЕ), умения распознавать и купировать гипогликемии на ранних стадиях, а также способности адаптировать введение инсулина под различные жизненные ситуации. С появлением помповой инсулинотерапии часть этих факторов перестала доставлять неудобства пациентам, однако даже на помповой инсулинотерапии они по-прежнему нуждаются в частом контроле гликемии, самостоятельном введении болюсного инсулина с учетом ХЕ, а также в коррекции введения инсулина вручную при необходимости. Высокоперспективным в плане повышения качества жизни пациентов с СД1 является использование системы закрытой петли. Данный проект представляет собой подобие функционирования здоровой поджелудочной железы. Целью его является поддержание нормогликемии или уровня глюкозы крови в безопасном заданном диапазоне посредством автоматической регулировки базальной и болюсной скорости секреции инсулина с помощью помпы. Регулирование подачи инсулина помпой осуществляется в соответствии с показаниями системы непрерывного мониторирования глюкозы. В статье представлен клинический случай использования этой системы пациентом с СД1.</p></abstract><trans-abstract xml:lang="en"><p>The urgency of the problem of type 1 diabetes mellitus (T1DM) does not lose ground over time due to the peculiarities of the course of the disease, the need for radical lifestyle correction, which leads to a decrease in the quality of life of patients, as well as a high probability of early disability and mortality of patients at a young age. Unsatisfactory glycemic control in T1DM is closely interrelated with both the risk of rapid development of chronic complications and the likelihood of acute complications. Achieving optimal glycemic control during insulin therapy requires frequent monitoring of glycemia, a detailed understanding of the rules for counting bread units, the ability to recognize and stop hypoglycemia at early stages, as well as the ability to adapt the administration of insulin to various life situations. With the advent of pump insulin therapy, some of these factors stopped to cause inconvenience to patients, however, even with pump insulin therapy, patients still need frequent monitoring of glycemia, self-administration of bolus insulin with counting bread units, as well as correction of insulin administration manually if necessary. The use of a closed loop system is highly promising in terms of improving the quality of life of patients with T1DM. This project is a semblance of a healthy pancreas. The goal is to maintain normoglycemia or blood glucose levels in a set range by automatically adjusting the basal and bolus insulin secretion rates using a pump. The adjustment of insulin secretion by the pump is carried out in accordance with the indications of the continuous glucose monitoring system. We present a clinical case of using this system by a patient with T1DM.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>искусственная поджелудочная железа</kwd><kwd>система закрытой петли</kwd><kwd>сахарный диабет 1 типа</kwd><kwd>непрерывный мониторинг глюкозы</kwd><kwd>инсулиновая помпа</kwd></kwd-group><kwd-group xml:lang="en"><kwd>artificial pancreas</kwd><kwd>closed loop system</kwd><kwd>type 1 diabetes mellitus</kwd><kwd>continuous glucose monitoring</kwd><kwd>insulin pump</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bergenstal RM, Tamborlane WV, Ahmann A et al. Effectiveness of sensoraugmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010; 363(4): 311–20. doi: 10.1056/NEJMoa1002853.</mixed-citation><mixed-citation xml:lang="en">Bergenstal R.M., Tamborlane W.V., Ahmann A., Buse J.B., Dailey G., Davis S.N., et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010; 363: 311–20. doi: 10.1056/NEJMoa1002853</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Волкова А.Р., Черная М.Е., Лискер А.В. с соавт. Вариабельность гликемии у пациентов с сахарным диабетом типа 1 на разных видах инсулинотерапии. Эндокринология: новости, мнения, обучение. 2019; 8(3): 38–43. doi: 10.24411/2304-9529-2019-13004.</mixed-citation><mixed-citation xml:lang="en">Volkova AR, Chernaya ME, Lisker AV et al. Variability of glycemia in patients with type 1 diabetes mellitus on different types of insulin therapy. Endocrinology: news, opinions, training 2019;8(3):38-43 (In Russ.) doi: 10.24411/2304–9529–2019– 13004</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ware J, Boughton CK, Allen JM et al; DAN05 Consortium. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: A multicentre 6-month randomised controlled trial. Lancet Digit Health. 2022; 4(4): e245–e255. doi: 10.1016/S2589-7500(22)00020-6.</mixed-citation><mixed-citation xml:lang="en">Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell FM, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Hood KK, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R; DAN05 Consortium. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. Lancet Digit Health. 2022 Apr;4(4):e245-e255. doi: 10.1016/S2589-7500(22)00020-6</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kadish AH. Automation control of blood sugar a servomechanism for glucose monitoring and control. Trans Am Soc Artif Intern Organs. 1963; 9: 363–67.</mixed-citation><mixed-citation xml:lang="en">Saunders A, Messer LH, Forlenza GP. MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy. Expert Rev Med Devices. 2019 Oct;16(10):845-853. doi: 10.1080/17434440.2019.1670639</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fogt EJ, Dodd LM, Jenning EM, Clemens AH. Development and evaluation of a glucose analyzer for a glucose controlled insulin infusion system (Biostator). Clin Chem. 1978; 24(8): 1366–72. doi: 10.1093/clinchem/24.8.1366.</mixed-citation><mixed-citation xml:lang="en">Volkova A.R., Chernaya M.E., Lisker A.V., Vlasova K.A. Analysis of the experience of using insulin therapy with the closed loop method among patients with type 1 diabetes in Russia. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (1): 35–41. doi: 10.33029/2304-9529-2020-9-1-35-41 (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Shichiri M, Kawamori R, Hakui N, Yamasaki Y, Abe H. Closed-loop glycemic control with a wearable artificial endocrine pancreas. Variations in daily insulin requirements to glycemic response. Diabetes. 1984; 33(12): 1200–2. doi: 10.2337/diab.33.12.1200.</mixed-citation><mixed-citation xml:lang="en">Kadish AH. Automation Control of Blood Sugar a Servomechanism for Glucose Monitoring and Control. Trans Am Soc Artif Intern Organs (1963) 9:363–67</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta A. Current diabetes technology: striving for the artificial pancreas. BMJ Open. 2019; 9(6); e027856. doi: 10.1136/bmjopen-2018–027856.</mixed-citation><mixed-citation xml:lang="en">Fogt EJ, Dodd LM, Jenning EM, Clemens AH. Development and Evaluation of a Glucose Analyzer for a Glucose Controlled Insulin Infusion System (Biostator). Clin Chem (1978) 24:1366–72. doi: 10.1093/clinchem/24.8.1366</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">FDA News Release 12-20-2016: FDA expands indication for continuous glucose monitoring system, first to replace fingerstick testing for diabetes treatment decision. URL: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm534056.htm (date of access – 21.01.2025).</mixed-citation><mixed-citation xml:lang="en">Shichiri M, Kawamori R, Hakui N, Yamasaki Y, Abe H. Closed-Loop Glycemic Control With a Wearable Artificial Endocrine Pancreas. Variations in Daily Insulin Requirements to Glycemic Response. Diabetes (1984) 33:1200–02. doi: 10.2337/diab.33.12.1200</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Danne T, Nimri R, Battelino T et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017; 40(12): 1631–40. doi: 10.2337/dc17-1600.</mixed-citation><mixed-citation xml:lang="en">Russell S.J., El-Khatib F.H., Sinha M., Magyar K.L., McKeon K., Goergen L.G. et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes // N. Engl. J. Med. 2014. Vol. 371. P. 313–325. doi: 10.1056/NEJMoa1314474Allen N., Gupta A. Current diabetes technology: striving for the Artificial pancreas // BMJ Open. 2019. Vol. 9, N 6. P. e027856. doi: 10.1136/bmjopen-2018–027856.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bergenstal RM, Beck RW, Close KL et al. Glucose management indicator (GMI): A new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018; 41(11): 2275–80. doi: 10.2337/dc18-1581.</mixed-citation><mixed-citation xml:lang="en">FDA News Release 12-20-2016: FDA expands indication for continuous glucose monitoring system, first to replace fingerstick testing for diabetes treatment decision. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm534056.htm</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Волкова А.Р., Черная М.Е., Лискер А.В., Власова К.А. Анализ опыта применения инсулинотерапии методом закрытой петли у пациентов с сахарным диабетом 1-го типа в России. Эндокринология: новости, мнения, обучение. 2020; 9(1): 35–41. doi: 10.33029/2304-9529-2020-9-1-35-41.</mixed-citation><mixed-citation xml:lang="en">Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41:2275–2280. doi: 10.2337/dc18-1581</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Bekiari E, Kitsios K, Thabit H et al. Artificial pancreas treatment for outpatients with type 1 diabetes: Systematic review and meta-analysis. BMJ. 2018; 361: k1310. doi: 10.1136/bmj.k1310</mixed-citation><mixed-citation xml:lang="en">Bekiari E., Kitsios K., Thabit H., et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ. 2018; 361. doi: https://doi.org/10.1136/bmj.k1310</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Brown SA, Kovatchev BP, Raghinaru D. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019; 381(18): 1707–17. doi: 10.1056/NEJMoa1907863.</mixed-citation><mixed-citation xml:lang="en">Brown S.A., Kovatchev B.P., Raghinaru D. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes // N. Engl. J. Med. 2019. Vol. 381. P. 1707–1717. doi: 10.1056/NEJMoa1907863</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
